Tag: bisantrene dihydrochloride
Aussie biotech firm completes bisantrene cGMP API manufacturing with Indian partner
Race Oncology Limited announced that Laurus Labs, an India-based pharmaceutical manufacturer, has produced its first batch of bisantrene dihydrochloride, Race’s active pharmaceutical ingredient (API), to a standard that meets the quality specified under the ‘Code of Good Manufacturing Practice’ (cGMP).
Featured Article
From cost exposure to cost control: Using energy flexibility to protect margins
Electricity price volatility is reshaping the cost base of Australian manufacturing, challenging long-held assumptions that energy can be treated as a stable operational input.
